-transparent.png){kind=logo}
Alpha 1-antitrypsin (alpha 1-AT) is the major inhibitor of proteinase 3 (PR3), the main target antigen of antineutrophil cytoplasm antibodies (ANCA) in Wegener's granulomatosis. alpha 1-AT is encoded by a polymorphic gene, with over 75 alleles, defining severely, medium and non-deficient protease inhibitor (PI) phenotypes. We describe the association of severely and medium deficient PI phenotypes with anti-PR3 positive systemic vasculitis, and postulate a pathogenetic role for alpha 1-AT deficiency and the occurrence of ANCA, with specificity for PR3 in a subgroup of patients with Wegener's granulomatosis.
Related Publications
V L Esnault, and
A Testa, and
M Audrain, and
C Rogé, and
M Hamidou, and
J H Barrier, and
R Sesboüé, and
J P Martin, and
P Lesavre
August 1997,
European journal of clinical investigation,
V L Esnault, and
A Testa, and
M Audrain, and
C Rogé, and
M Hamidou, and
J H Barrier, and
R Sesboüé, and
J P Martin, and
P Lesavre
January 1993,
Advances in experimental medicine and biology,
V L Esnault, and
A Testa, and
M Audrain, and
C Rogé, and
M Hamidou, and
J H Barrier, and
R Sesboüé, and
J P Martin, and
P Lesavre
February 1997,
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
V L Esnault, and
A Testa, and
M Audrain, and
C Rogé, and
M Hamidou, and
J H Barrier, and
R Sesboüé, and
J P Martin, and
P Lesavre
October 1991,
The Journal of rheumatology,
V L Esnault, and
A Testa, and
M Audrain, and
C Rogé, and
M Hamidou, and
J H Barrier, and
R Sesboüé, and
J P Martin, and
P Lesavre
September 1995,
Kidney international,
V L Esnault, and
A Testa, and
M Audrain, and
C Rogé, and
M Hamidou, and
J H Barrier, and
R Sesboüé, and
J P Martin, and
P Lesavre
June 1994,
Presse medicale (Paris, France : 1983),
V L Esnault, and
A Testa, and
M Audrain, and
C Rogé, and
M Hamidou, and
J H Barrier, and
R Sesboüé, and
J P Martin, and
P Lesavre
June 1987,
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
V L Esnault, and
A Testa, and
M Audrain, and
C Rogé, and
M Hamidou, and
J H Barrier, and
R Sesboüé, and
J P Martin, and
P Lesavre
May 1995,
Clinical and experimental immunology,
V L Esnault, and
A Testa, and
M Audrain, and
C Rogé, and
M Hamidou, and
J H Barrier, and
R Sesboüé, and
J P Martin, and
P Lesavre
March 2000,
Clinical and experimental immunology,
V L Esnault, and
A Testa, and
M Audrain, and
C Rogé, and
M Hamidou, and
J H Barrier, and
R Sesboüé, and
J P Martin, and
P Lesavre
January 1997,
Experimental and clinical immunogenetics,
